Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:38:59 2024-04-24 am EDT Pre-market 02:05:10 am
87.7 EUR -1.29% Intraday chart for Sanofi 88.5 +0.91%
Sales 2024 * 46.05B 49.32B Sales 2025 * 49.63B 53.15B Capitalization 110B 117B
Net income 2024 * 7.34B 7.86B Net income 2025 * 8.69B 9.31B EV / Sales 2024 * 2.53 x
Net Debt 2024 * 6.97B 7.47B Net Debt 2025 * 2.75B 2.94B EV / Sales 2025 * 2.26 x
P/E ratio 2024 *
15 x
P/E ratio 2025 *
12.8 x
Employees 86,088
Yield 2024 *
4.39%
Yield 2025 *
4.66%
Free-Float 87.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.29%
1 week+1.76%
Current month-3.58%
1 month-1.07%
3 months-5.24%
6 months-11.36%
Current year-2.30%
More quotes
1 week
85.07
Extreme 85.07
89.65
1 month
85.07
Extreme 85.07
92.04
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
105.18
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 39 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 64 20-05-21
Director/Board Member 52 20-04-27
More insiders
Date Price Change Volume
24-04-24 87.7 -1.29% 1,576,217
24-04-23 88.85 +0.77% 1,062,952
24-04-22 88.17 +1.47% 1,454,519
24-04-19 86.89 +1.95% 1,871,390
24-04-18 85.23 -1.10% 1,813,622

Real-time Euronext Paris, April 24, 2024 at 11:38 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
87.7 EUR
Average target price
107.8 EUR
Spread / Average Target
+22.87%
Consensus